| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.025 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.027 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |